Day One Biopharmaceuticals, Inc. (DAWN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DAWN Stock Price Chart Interactive Chart >
DAWN Price/Volume Stats
| Current price | $20.03 | 52-week high | $28.35 |
| Prev. close | $19.62 | 52-week low | $5.44 |
| Day low | $19.37 | Volume | 887,000 |
| Day high | $20.43 | Avg. volume | 827,335 |
| 50-day MA | $21.86 | Dividend yield | N/A |
| 200-day MA | $15.11 | Market Cap | 1.47B |
Day One Biopharmaceuticals, Inc. (DAWN) Company Bio
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Latest DAWN News From Around the Web
Below are the latest news stories about DAY ONE BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate DAWN as an investment opportunity.
Day One Appoints Garry Nicholson as Chairman of the Board of DirectorsSOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncolog |
Day One Biopharmaceuticals (DAWN) Receives a Buy from JonesTradingJonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Day One Biopharmaceuticals (DAWN - Research Report) today and set a price target of $40.00. The company's shares closed last Friday at $23.80.According to TipRanks, Roy is a 4-star analyst with an average return of 4.2% and a 32.74% success rate. Roy covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Curis, and AVEO Pharma.Currently, the analyst consensus on Day One Biopharmaceuticals is a Strong Buy with an average price target of $36.75.See Insiders’ Hot Stocks on TipRanks >> The company has a one-year high of $28.70 and a one-year low of $5.44. |
Here's What Could Help Day One Biopharmaceuticals, Inc. (DAWN) Maintain Its Recent Price StrengthDay One Biopharmaceuticals, Inc. (DAWN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
Day One Reports Second Quarter 2022 Financial Results and Corporate ProgressReported positive initial data from ongoing pivotal FIREFLY-1 study with tovorafenib (DAY101) in relapsed pediatric low-grade glioma (pLGG); topline results for full pivotal study population expected in the first quarter of 2023 Expanded development of tovorafenib with initiation of pivotal Phase 3 FIREFLY-2/LOGGIC clinical trial evaluating tovorafenib as a front-line therapy in pLGG Completed $172.5 million upsized public offering providing funding into 2025 SOUTH SAN FRANCISCO, Calif., Aug. 04 |
Day One to Participate in the 2022 Wedbush PacGrow Healthcare Virtual ConferenceSOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Virtual Conference. The panel entitled “Bullseye - Targeted Oncology - Finding Needles in Plain Sight” will be held on Tues |
DAWN Price Returns
| 1-mo | -15.70% |
| 3-mo | 0.40% |
| 6-mo | 87.72% |
| 1-year | -18.54% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 18.87% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...